{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:27:09Z","timestamp":1790404029840,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1038\/ctg.2016.32","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T12:34:40Z","timestamp":1464266080000},"page":"e173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome"],"prefix":"10.14309","volume":"7","author":[{"given":"Andr\u00e9s","family":"Acosta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Linker","family":"Nord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber V","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J","family":"Lueke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane D","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A","family":"Szarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R","family":"Zinsmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Fodor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210317","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2036.2007.03399.x","article-title":"Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome.","volume":"26","author":"Thabane","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R2-5-20210317","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.gastro.2007.04.005","article-title":"The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects.","volume":"133","author":"Kassinen","year":"2007","journal-title":"Gastroenterology"},{"key":"R3-5-20210317","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1572-0241.2005.40312.x","article-title":"Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.","volume":"100","author":"Malinen","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R4-5-20210317","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.3748\/wjg.15.5936","article-title":"Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification.","volume":"15","author":"Lyra","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R5-5-20210317","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0016-5085(83)90012-4","article-title":"Passage of carbohydrate into the colon. Direct measurements in humans.","volume":"85","author":"Stephen","year":"1983","journal-title":"Gastroenterology"},{"key":"R6-5-20210317","first-page":"512","article-title":"Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome.","volume":"22","author":"Tana","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"R7-5-20210317","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.31.4.443","article-title":"Colonic capacitance and transit in man: modulation by luminal contents and drugs.","volume":"31","author":"Kamath","year":"1990","journal-title":"Gut"},{"key":"R8-5-20210317","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/0016-5085(86)90445-2","article-title":"Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acid.","volume":"91","author":"Spiller","year":"1986","journal-title":"Gastroenterology"},{"key":"R9-5-20210317","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2982.2010.01637.x","article-title":"PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity.","volume":"23","author":"Nelson","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"R10-5-20210317","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.gastro.2006.11.014","article-title":"The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats.","volume":"132","author":"Winston","year":"2007","journal-title":"Gastroenterology"},{"key":"R11-5-20210317","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1021\/pr2003598","article-title":"Metabolomics of faecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome.","volume":"10","author":"Le Gall","year":"2011","journal-title":"J Proteome Res"},{"key":"R12-5-20210317","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.3748\/wjg.v16.i36.4532","article-title":"Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome.","volume":"16","author":"Malinen","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R13-5-20210317","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation.","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"R14-5-20210317","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome.","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"R15-5-20210317","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence.","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R16-5-20210317","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/apt.12735","article-title":"Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.","volume":"39","author":"Schoenfeld","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-5-20210317","first-page":"89","article-title":"Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.","volume":"52","author":"Cuoco","year":"2006","journal-title":"Minerva Gastroenterol Dietol"},{"key":"R18-5-20210317","first-page":"1314","article-title":"Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.","volume":"17","author":"Scarpellini","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R19-5-20210317","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/gut.2009.205476","article-title":"Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS.","volume":"60","author":"Yu","year":"2011","journal-title":"Gut"},{"key":"R20-5-20210317","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2015.07.032","article-title":"Scintigraphy demonstrates high rate of false-positive results from glucose breath tests for small bowel bacterial overgrowth.","volume":"14","author":"Lin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R21-5-20210317","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.3748\/wjg.v20.i10.2482","article-title":"Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.","volume":"20","author":"Ghoshal","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R22-5-20210317","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.13437","article-title":"Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.","volume":"43","author":"Pimentel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-5-20210317","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0025-6196(12)62169-7","article-title":"Assessment of functional gastrointestinal disease: the Bowel Disease Questionnaire.","volume":"65","author":"Talley","year":"1990","journal-title":"Mayo Clin Proc"},{"key":"R24-5-20210317","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cgh.2008.02.060","article-title":"Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome.","volume":"6","author":"Camilleri","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R25-5-20210317","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/00365528909089259","article-title":"Does smoking tighten the gut?","volume":"24","author":"Prytz","year":"1989","journal-title":"Scand J Gastroenterol"},{"key":"R26-5-20210317","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1046\/j.1365-2036.2000.00754.x","article-title":"The effects of smoking and indomethacin on small intestinal permeability.","volume":"14","author":"Suenaert","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-5-20210317","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1111\/j.1365-2982.2012.01969.x","article-title":"The effect of aspirin and smoking on urinary excretion profiles of lactulose and mannitol in young women: toward a dynamic, aspirin augmented, test of gut mucosal permeability.","volume":"24","author":"Sequeira","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"R28-5-20210317","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/gut.27.11.1292","article-title":"Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine.","volume":"27","author":"Bjarnason","year":"1986","journal-title":"Gut"},{"key":"R30-5-20210317","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2982.2009.01442.x","article-title":"Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort.","volume":"22","author":"Manabe","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"R31-5-20210317","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/j.1365-2982.2009.01361.x","article-title":"Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion.","volume":"22","author":"Camilleri","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"R32-5-20210317","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.clinbiochem.2008.03.016","article-title":"A liquid chromatographymass spectrometry method for the evaluation of intestinal permeability.","volume":"41","author":"Lostia","year":"2008","journal-title":"Clin Biochem"},{"key":"R33-5-20210317","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1126\/science.1195979","article-title":"Deep-sea oil plume enriches indigenous oil-degrading bacteria.","volume":"330","author":"Hazen","year":"2010","journal-title":"Science"},{"key":"R34-5-20210317","doi-asserted-by":"crossref","first-page":"e99801","DOI":"10.1371\/journal.pone.0099801","article-title":"Coupling genetic and chemical microbiome profiling reveals heterogeneity of archaeome and bacteriome in subsurface biofilms that are dominated by the same archaeal species.","volume":"9","author":"Probst","year":"2014","journal-title":"PLoS One"},{"key":"R35-5-20210317","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1515\/CCLM.2003.247","article-title":"Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method.","volume":"41","author":"Tagliacozzi","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"R36-5-20210317","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on fecal bile acids and bowel functions in diarrhea-predominant irritable bowel syndrome.","volume":"41","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-5-20210317","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cgh.2012.05.006","article-title":"Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea.","volume":"10","author":"Wong","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R38-5-20210317","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.cgh.2013.04.020","article-title":"Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.","volume":"11","author":"Shin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R39-5-20210317","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1128\/JCM.16.2.355-360.1982","article-title":"Analysis of short-chain acids from anaerobic bacteria by high-performance liquid chromatography.","volume":"16","author":"Guerrant","year":"1982","journal-title":"J Clin Microbiol"},{"key":"R40-5-20210317","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/abio.1996.0123","article-title":"A gas chromatographic analysis of fecal short-chain fatty acids, using the direct injection method.","volume":"236","author":"Tangerman","year":"1996","journal-title":"Anal Biochem"},{"key":"R41-5-20210317","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2362.2008.02075.x","article-title":"Clinical relevance of measuring colonic permeability.","volume":"39","author":"Haas","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"R42-5-20210317","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1572-0241.2006.00672.x","article-title":"Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes.","volume":"101","author":"Dunlop","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R43-5-20210317","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/MCO.0b013e32835665fa","article-title":"Butyrate: implications for intestinal function.","volume":"15","author":"Leonel","year":"2012","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R44-5-20210317","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s10620-014-3157-8","article-title":"Antibiotic treatment of constipation-predominant irritable bowel syndrome.","volume":"59","author":"Pimentel","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R45-5-20210317","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijantimicag.2013.12.008","article-title":"In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.","volume":"43","author":"Pistiki","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R46-5-20210317","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10620-013-2675-0","article-title":"The effect of rifaximin on gut flora and Staphylococcus resistance.","volume":"58","author":"Kim","year":"2013","journal-title":"Dig Dis Sci"},{"key":"R47-5-20210317","doi-asserted-by":"crossref","first-page":"S655","DOI":"10.1016\/S0016-5085(15)32213-7","article-title":"Characterization of stool microbiota in subjects with IBS-D receiving repeat treatments with rifaximin in the TARGET 3 study.","volume":"148","author":"Pimentel","year":"2015","journal-title":"Gastroenterology"},{"key":"R48-5-20210317","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/gmic.25723","article-title":"Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship.","volume":"4","author":"Ridlon","year":"2013","journal-title":"Gut Microbes"},{"key":"R49-5-20210317","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/apt.13351","article-title":"Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders.","volume":"42","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"RU50-5-20210317","first-page":"G919","article-title":"Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls.","volume":"301","author":"Rao","year":"2011","journal-title":"Am J Physiol"},{"key":"RU51-5-20210317","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/ajg.2014.215","article-title":"Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea.","volume":"109","author":"Camilleri","year":"2014","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical and Translational Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ctg201632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ctg201632","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01720094-201605000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ctg201632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:12:48Z","timestamp":1786547568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01720094-201605000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1038\/ctg.2016.32","relation":{},"ISSN":["2155-384X"],"issn-type":[{"value":"2155-384X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}